Nicholas Vogelzang, MD of Comprehensive Cancer Center @CCCNevada discusses the single arm, phase 2, TRITON2 clinical trial supported FDA approval of Rubraca in mCRPC
Nicholas Vogelzang, MD on Phase 2 TRITON2 Clinical Trial @CCCNevada
Nicholas Vogelzang, MD of Comprehensive Cancer Center @CCCNevada discusses the single arm, phase 2, TRITON2 clinical trial supported FDA approval of Rubraca in mCRPC